Curaleaf Laboratories and Vericura today announced an agreement to strengthen the manufacturing and distribution of medical cannabis products across the United Kingdom.
Curaleaf Laboratories, one of the UK-leading pharmaceutical-grade medical cannabis manufacturers, is delighted to announce a partnership with Berlin-based Sanity Group, a European life science company focused on cannabinoids and wellbeing products.
Earlier this week, we looked at the dramatic shifts in the UK medical cannabis flower market over the last three years.
Curaleaf Laboratories, one of the UK’s leading providers of medicinal cannabis products, is pleased to announce a landmark partnership with Australian Natural Therapeutics Group (ANTG), one of Australia’s most respected producers of pharmaceutical-grade medicinal cannabis.
Accredited Medical Cannabis Symposium Could ‘Benefit Thousands of Patients’, Says Expert
Curaleaf Laboratories has been confirmed as headline sponsor of the inaugural Cannabis Health Symposium, taking place on 25 November 2025 at Conway Hall, London.
The UK’s medical cannabis industry is now the second largest in Europe, second only to Germany, thanks to consistent and sustained growth over the last seven years.
As the UK’s medical cannabis patient population pushes past an estimated 60,000, questions about market maturity, patient access, and regulatory reform are more pressing than ever.
Dalgety, a UK-based EU-GMP certified medical cannabis cultivator, is pleased to announce a strategic partnership with Curaleaf Laboratories, a trusted name in cannabis medicine and pharmaceutical-quality cannabinoid innovation.
